An Analysis of the Changes in the Sarcoma Tumor Immune Microenvironment Following Trabectedin

Trial Profile

An Analysis of the Changes in the Sarcoma Tumor Immune Microenvironment Following Trabectedin

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs Trabectedin (Primary)
  • Indications Sarcoma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 08 Feb 2018 Planned End Date changed from 1 Feb 2019 to 1 May 2019.
    • 08 Feb 2018 Planned primary completion date changed from 1 Feb 2019 to 1 May 2019.
    • 08 Feb 2018 Planned initiation date changed from 1 Feb 2018 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top